Considering that there is no definite conclusion on the efficacy and safety of switching from
potent P2Y 12 inhibitors to clopidogrel, we conducted a systematic review and meta …

Aims: Patients with acute coronary syndrome undergoing percutaneous coronary
intervention (PCI) are recommended to be placed on potent P2Y12 blockade. However, the …

Background Dual antiplatelet therapy (DAPT) is usually recommended for acute coronary
syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Despite the …

Introduction We aimed to evaluate the clinical benefits of a de-escalation strategy from
prasugrel or ticagrelor to clopidogrel versus continuation of prasugrel or ticagrelor along …

Objective: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the
cornerstone of treatment in patients with acute coronary syndromes (ACS) and in those …

In acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention
(PCI), treatment with the P2Y12 inhibitors ticagrelor or prasugrel is recommended over …

Essentials• The comparative efficacy and safety of antiplatelet agents in 'real life'is not clear.•
We recruited acute coronary syndrome patients receiving percutaneous coronary …

Purpose To assess the efficacy and safety of low-dose prasugrel compared to clopidogrel
based on the occurrence of major adverse cardiac events (MACEs) and major bleeding in …

Background: According to ACC/AHA guidelines, a minimum of 1 year of dual anti-platelet
therapy (DAPT) consisting of aspirin and a platelet ADP-receptor antagonist (P2Y12 …

Background: In TRITON-TIMI 38 trial, prasugrel was shown to be superior to clopidogrel in
preventing ischemic events in patients with an acute coronary syndrome (ACS) who …